AIM: To investigate the prognostic value of CD44 variant 6 (CD44v6), a membranous adhesion molecule, in rectal cancer. METHODS: Altogether, 210 rectal cancer samples from 214 patients treated with short-course radioth...AIM: To investigate the prognostic value of CD44 variant 6 (CD44v6), a membranous adhesion molecule, in rectal cancer. METHODS: Altogether, 210 rectal cancer samples from 214 patients treated with short-course radiotherapy (RT, n = 90), long-course (chemo) RT (n = 53) or surgery alone (n = 71) were studied with immunohistochemistry for CD44v6. The extent and intensity of membranous and cytoplasmic CD44v6 staining, and the intratumoral membranous staining pattern, were analyzed.RESULTS: Membranous CD44v6 expression was seen in 84% and cytoplasmic expression in 81% of the cases. In 59% of the tumors with membranous CD44v6 expression, the staining pattern in the invasive front was determined as "front-positive" and in 41% as "front-negative". The latter pattern was associated with narrower circumferential margin (P = 0.01), infiltrative growth pattern (P < 0.001), and shorter disease-free survival in univariate survival analysis (P = 0.022) when compared to the "front-positive" tumors. CONCLUSION: The lack of membranous CD44v6 in the rectal cancer invasive front could be used as a method to identify patients at increased risk for recurrent disease.展开更多
This study aimed to explore the molecular mechanism in tumor invasion and metastasis. The ex-pression of matrix metalloproteinase-2,-9 (MMP-2,MMP-9), tissue inhibitor-1 of matrix metalloprote inase(TIMP-1) , cell adh...This study aimed to explore the molecular mechanism in tumor invasion and metastasis. The ex-pression of matrix metalloproteinase-2,-9 (MMP-2,MMP-9), tissue inhibitor-1 of matrix metalloprote inase(TIMP-1) , cell adhesion molecule 44 variant 6 (CD44v6) , HER2/neu and p53 was investigated in 154 pa-tients with head and neck squamous cell carcinoma (SCC) by ABC and ImmunoMax immunohistochemical method. Their clinical relevance and correlation were analysed. The expression of MMP-2, MMP-9, TIMP-1,CD44v6, HER2/neu and p53 was found in cancer cells in 87.01%, 85.71%, 68. 18%, 98.05%,55.19% and 50.65% cases respectively. Linear regression and correlation analysis revealed that there wasclose positive relationship ( P < 0.05) between the expression of MMP-2 and MMP-9, TIMP-1 and CD44v6,HER2/neu and MMP-9, MMP-2 and p53. Up-regulation of MMP-2 was accompanied by advanced T stage( P < 0.01 ) . There was also a trend of MMP-2 expression being related with tumor metastasis. Increased ex-pression of HER2/neu was found in patients with tumor recurrence( P < 0.05 ) . The expression of TIMP-1 washigher in laryngeal cancer than that in pharyngeal cancer, and higher in keratinizing and non-keratlnizing SCC than that in basaloid SCC ( P < 0.05 ) . These findings suggested that MMP-2 and MMP-9, HER2/neu andMMP-9, MMP-2 and p53 had a coordinate function in aggression of tumor; that MMP-2 had a more important function than MMP-9 in tumor invasion and metastasis; and that HER2/neu might serve as a biomarker forpoor prognosis in HNSCC.展开更多
目的构建含人/鼠嵌合粘附分子CD44拼接变异体6(chimeric human and mouse CD44 splice variant 6,h/mCD44v6)基因真核表达质粒pcDNA3.1(+)-h/mCD44v6,并进行表达。方法通过PCR扩增h/mCD44v6的全基因cDNA,将扩增的cDNA克隆至PGM-Teasy,...目的构建含人/鼠嵌合粘附分子CD44拼接变异体6(chimeric human and mouse CD44 splice variant 6,h/mCD44v6)基因真核表达质粒pcDNA3.1(+)-h/mCD44v6,并进行表达。方法通过PCR扩增h/mCD44v6的全基因cDNA,将扩增的cDNA克隆至PGM-Teasy,测序后插入pcD-NA3.1(+)真核表达质粒,构建重组真核表达质粒pcD-NA3.1(+)-h/mCD44v6,经限制内切酶酶切分析及测序鉴定后,用脂质体转染B16细胞,通过RT-PCR扩增出B16/pcDNA3.1(+)-h/mCD44v6细胞株中h/mCD44v6全段基因cDNA。结果经4轮PCR,成功扩增出h/mCD44v6的cD-NA全长基因,成功构建了真核表达质粒pcDNA3.1(+)-h/mCD44v6,通过RT-PCR方法证实该质粒能在B16真核细胞中正确表达;建立了稳定的细胞株B16/pcDNA3.1(+)-h/mCD44v6。结论成功克隆和构建了h/mCD44v6的真核表达质粒pcDNA3.1(+)-h/mCD44v6,为进一步研究h/mCD44v6的新功能和免疫治疗奠定了基础。展开更多
基金The Special Government Funding (EVO) allocated to Turku University Hospitalthe Turku University Foundation, to Avoranta ST+1 种基金the Cancer Society of South-Western Finland, to Sundstrm JTTthe Finnish Society for Therapeutic Radiology and Oncology, to Korkeila EA
文摘AIM: To investigate the prognostic value of CD44 variant 6 (CD44v6), a membranous adhesion molecule, in rectal cancer. METHODS: Altogether, 210 rectal cancer samples from 214 patients treated with short-course radiotherapy (RT, n = 90), long-course (chemo) RT (n = 53) or surgery alone (n = 71) were studied with immunohistochemistry for CD44v6. The extent and intensity of membranous and cytoplasmic CD44v6 staining, and the intratumoral membranous staining pattern, were analyzed.RESULTS: Membranous CD44v6 expression was seen in 84% and cytoplasmic expression in 81% of the cases. In 59% of the tumors with membranous CD44v6 expression, the staining pattern in the invasive front was determined as "front-positive" and in 41% as "front-negative". The latter pattern was associated with narrower circumferential margin (P = 0.01), infiltrative growth pattern (P < 0.001), and shorter disease-free survival in univariate survival analysis (P = 0.022) when compared to the "front-positive" tumors. CONCLUSION: The lack of membranous CD44v6 in the rectal cancer invasive front could be used as a method to identify patients at increased risk for recurrent disease.
文摘This study aimed to explore the molecular mechanism in tumor invasion and metastasis. The ex-pression of matrix metalloproteinase-2,-9 (MMP-2,MMP-9), tissue inhibitor-1 of matrix metalloprote inase(TIMP-1) , cell adhesion molecule 44 variant 6 (CD44v6) , HER2/neu and p53 was investigated in 154 pa-tients with head and neck squamous cell carcinoma (SCC) by ABC and ImmunoMax immunohistochemical method. Their clinical relevance and correlation were analysed. The expression of MMP-2, MMP-9, TIMP-1,CD44v6, HER2/neu and p53 was found in cancer cells in 87.01%, 85.71%, 68. 18%, 98.05%,55.19% and 50.65% cases respectively. Linear regression and correlation analysis revealed that there wasclose positive relationship ( P < 0.05) between the expression of MMP-2 and MMP-9, TIMP-1 and CD44v6,HER2/neu and MMP-9, MMP-2 and p53. Up-regulation of MMP-2 was accompanied by advanced T stage( P < 0.01 ) . There was also a trend of MMP-2 expression being related with tumor metastasis. Increased ex-pression of HER2/neu was found in patients with tumor recurrence( P < 0.05 ) . The expression of TIMP-1 washigher in laryngeal cancer than that in pharyngeal cancer, and higher in keratinizing and non-keratlnizing SCC than that in basaloid SCC ( P < 0.05 ) . These findings suggested that MMP-2 and MMP-9, HER2/neu andMMP-9, MMP-2 and p53 had a coordinate function in aggression of tumor; that MMP-2 had a more important function than MMP-9 in tumor invasion and metastasis; and that HER2/neu might serve as a biomarker forpoor prognosis in HNSCC.
文摘目的构建含人/鼠嵌合粘附分子CD44拼接变异体6(chimeric human and mouse CD44 splice variant 6,h/mCD44v6)基因真核表达质粒pcDNA3.1(+)-h/mCD44v6,并进行表达。方法通过PCR扩增h/mCD44v6的全基因cDNA,将扩增的cDNA克隆至PGM-Teasy,测序后插入pcD-NA3.1(+)真核表达质粒,构建重组真核表达质粒pcD-NA3.1(+)-h/mCD44v6,经限制内切酶酶切分析及测序鉴定后,用脂质体转染B16细胞,通过RT-PCR扩增出B16/pcDNA3.1(+)-h/mCD44v6细胞株中h/mCD44v6全段基因cDNA。结果经4轮PCR,成功扩增出h/mCD44v6的cD-NA全长基因,成功构建了真核表达质粒pcDNA3.1(+)-h/mCD44v6,通过RT-PCR方法证实该质粒能在B16真核细胞中正确表达;建立了稳定的细胞株B16/pcDNA3.1(+)-h/mCD44v6。结论成功克隆和构建了h/mCD44v6的真核表达质粒pcDNA3.1(+)-h/mCD44v6,为进一步研究h/mCD44v6的新功能和免疫治疗奠定了基础。
